MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.380 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
38 39 Next >
News headline image
Why U.S. Stocks Are Trading Higher Ahead Of Fed Decision; Alphabet Earnings Miss Views ↗
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 250 points on Wednesday. 
Via Benzinga
News headline image
Cassava (SAVA) Stock Falls 30% on Report of Criminal Probe ↗
SAVA stock is tumbling 30% in pre-market trading on a report that the Justice Department had launched a criminal probe of the company. 
Via InvestorPlace
News headline image
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Cassava Sciences Shares Plunge After Criminal Investigation Report ↗
 
Via Benzinga
News headline image
Recap: Cassava Sciences Q1 Earnings ↗
Cassava Sciences (NASDAQ:SAVA) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Cassava Sciences May Be Heading Below $10 Per Share ↗
Cassava Sciences is facing criticism around its lead drug candidate. If that drug doesn't work, SAVA stock has a lot farther left to fall. 
Via InvestorPlace
News headline image
Benzinga Before The Bell: Twitter Shareholder Proposal Date Set, T-Mobile's Strong FY22 Outlook, Shopify's Job Cuts And Other Top Financial Stories Wednesday, July 27 ↗
Reuters Monkeypox Emergency Could Last Months, According To Experts 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Good morning, investor! Wednesday starts with a breakdown of the biggest pre-market stock movers for traders to keep an eye on! 
Via InvestorPlace
News headline image
Why Is F45 Training Holdings Down By 56%? Here Are 28 Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Dave Inc. (NASDAQ: DAVE) rose 56.9% to $0.9826 in pre-market trading. Dave is expected to release its second quarter 2022 financial results on Thursday, August 11, 2022. 
Via Benzinga
News headline image
7 Meme Stocks Trading at a Massive Discount Right Now ↗
'Meme mania' has long since passed, but there may be an opportunity with these seven meme stocks trading at a discount right now. 
Via InvestorPlace
News headline image
These Biotechs Are Reportedly Reinvigorating Alzheimer's Disease Research With Novel Drugs That Push Beyond Traditional Approaches ↗
More than 55 million people worldwide have dementia — with about 60% to 70% of those cases resulting from Alzheimer’s disease — and that number is expected to triple by 2050. 
Via Benzinga
News headline image
CASSAVA SCIENCES INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
News headline image
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It ↗
Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. 
Via Benzinga
News headline image
5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow Rise ↗
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. 
Via Benzinga
News headline image
Cassava Sciences, Inc. (NASDAQ:SAVA) Investor Alert: Investigation over Possible Violations of Securities Laws ↗
San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Cassava Sciences, Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
The 7 Best Meme Stocks to Buy Now ↗
The meme stock craze might never be what it was last year, but these meme stocks to buy that are still worth another look. 
Via InvestorPlace
News headline image
5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List ↗
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. 
Via Benzinga
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster... 
Via FinancialNewsMedia
News headline image
Short Squeeze Stocks: BBAI, MMAT and 3 Others Experts Think Are Ready to Pop ↗
Short squeeze stocks continue to be of interest to retail traders looking to pump up shares while pushing hedge funds out of a company. 
Via InvestorPlace
News headline image
How Is The Market Feeling About Cassava Sciences? ↗
Cassava Sciences's (NASDAQ:SAVA) short percent of float has risen 7.39% since its last report. The company recently reported that it has 11.46 million shares sold short, which is... 
Via Benzinga
News headline image
What Are Whales Doing With Cassava Sciences ↗
Someone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years ↗
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 25.46% on an annualized basis producing an average annual return of 37.25%. Currently, Cassava Sciences has a market... 
Via Benzinga
News headline image
Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms ↗
Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point. 
Via InvestorPlace
News headline image
Take Full Advantage of Weakness in Cassava Sciences Stock ↗
Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer’s treatment, it could see $140 again. 
Via InvestorPlace
News headline image
Cassava Sciences Is a Worthwhile Bet to Consider ↗
FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up. 
Via InvestorPlace
News headline image
CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
The Crowd Has Wisely Soured on Cassava Sciences Stock ↗
Recent headlines suggest Simulfilam has a slim chance of obtaining FDA approval, justifying the move of SAVA stock to lower prices. 
Via InvestorPlace
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story